Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.

  • Beam Therapeutics' Gains from Investment Securities fell 380370.37% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 8624.53%. This contributed to the annual value of $9.6 million for FY2024, which is 1606.46% up from last year.
  • As of Q3 2025, Beam Therapeutics' Gains from Investment Securities stood at -$1.0 million, which was down 380370.37% from $28000.0 recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Gains from Investment Securities peaked at $60.9 million during Q4 2021, and registered a low of -$12.5 million during Q4 2022.
  • Over the past 5 years, Beam Therapeutics' median Gains from Investment Securities value was $7.3 million (recorded in 2022), while the average stood at $8.1 million.
  • The largest annual percentage gain for Beam Therapeutics' Gains from Investment Securities in the last 5 years was 646840.45% (2025), contrasted with its biggest fall of 380370.37% (2025).
  • Beam Therapeutics' Gains from Investment Securities (Quarter) stood at $60.9 million in 2021, then tumbled by 120.48% to -$12.5 million in 2022, then skyrocketed by 247.31% to $18.4 million in 2023, then crashed by 32.98% to $12.3 million in 2024, then crashed by 108.12% to -$1.0 million in 2025.
  • Its Gains from Investment Securities was -$1.0 million in Q3 2025, compared to $28000.0 in Q2 2025 and $11.6 million in Q1 2025.